BJMO - volume 18, issue 8, december 2024
P. Vanclooster MD
While ESMO 2024 once again did not yield a phase III trial for brain tumours, it presented intriguing findings from early-phase clinical trials and translational studies. We highlight three of the most significant and promising trials related to brain tumours discussed at the conference, particularly focusing on IDH-mutated tumours, glioblastoma, and novel immunotherapy strategies.
(BELG J MED ONCOL 2024;18(8):337–340)
Read moreTo provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.